Nicotinic acetylcholine receptor alpha6beta2-containing (α6β2* nAChR)

Nicotinic acetylcholine receptors containing the alpha6 and beta2 subunits (α6β2*) are a specialized subtype of pentameric ligand-gated ion channels primarily expressed in the catecholaminergic nuclei of the midbrain, including the substantia nigra and ventral tegmental area (Quik & Wonnacott, 2011; Quik et al., 2011). These receptors play a critical role in modulating the release of dopamine in the striatum and nucleus accumbens, thereby influencing motor control, reward, and reinforcement pathways (Salminen et al., 2015; Luo et al., 2016). In Parkinson's disease, there is a selective and early loss of α6β2* receptors on nigrostriatal dopaminergic terminals, making them a target for neuroprotective and symptomatic therapies (Quik & Wonnacott, 2011; Henderson & Lester, 2015). Additionally, their involvement in the mesolimbic reward system makes them significant targets for treating nicotine and alcohol addiction (Salminen et al., 2015; Stafford, 2017). Pharmacological agents such as varenicline act as partial agonists at these receptors, while selective antagonists like α-conotoxins are used as research tools to study their specific functions (Gündisch et al., 2015). Developing highly selective small molecules remains a challenge due to the structural similarity between α6β2* and the more widely distributed α4β2* subtype (Quik & Wonnacott, 2011; Henderson & Lester, 2015).

Other names

Alpha6beta2 nicotinic receptorα6β2* nAChRNicotinic acetylcholine receptor alpha-6 beta-2CHRNA6-CHRNB2 receptorNeuronal nicotinic acetylcholine receptor alpha6beta2 subtype

Agonism or partial agonism at alpha6beta2-containing receptors stimulates presynaptic dopamine release in the striatum and nucleus accumbens, potentially providing neuroprotection or symptomatic relief in Parkinson's disease. Antagonism at these receptors blocks the rewarding effects of nicotine and other drugs of abuse, facilitating addiction treatment.